http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2049881-C
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J73-005 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J75-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J73-00 |
filingDate | 1991-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 1996-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02481c35c0508313a35cda689175dbe0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce763467799032659120d7a8700f1a99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7844a9d11e6e99c45d17b7e97a0601a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c37ee0e6c283f66ff94ea47d836f7e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfe1f89342193fd2f6aeed955d2bc10d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cd42dc1c2623c1726dec09944ff0205 |
publicationDate | 1996-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2049881-C |
titleOfInvention | Trialkylsilyl trifluormethanesulfonate mediated .alpha.-methylenic carbon functionalization of 4-aza-5.alpha.-androstan-3-one steroids |
abstract | A novel single-pot trialkylsilyl trifluoromethanesulfonate (R3Si-OTf) mediated process produces derivatives of 4-aza 3-keto steroids at the .alpha.-methylenic carbon through electrophilic substitution. These derivatives are useful in the preparation, through elimination of the substituent on the .alpha.-methylene carbon, of .DELTA.-1 olefin 4-aza 3-keto steroids which are potent inhibitors of 5-.alpha. reductase. 5.alpha.-dihydrotestosterone, which is the principal mediator of androgenic activity in some organs. Inhibitors of testosterone-5.alpha.-reductase have been shown to prevent or lessen symptoms of hyperandrogenic stimulation. Nayfe et al., [Steroids, 14, 269 (1969)] demonstrated in vitro that methyl 4-androsten-3-one-17.beta.-carboxylate was a testosterone-5.alpha.-reductase inhibitor. Voigt and Hsia, [Endocrinology, 92, 1216 (1973), Canadian Pat. No. 970,692], demonstrated that the above ester and the parent free acid, 4-androsten-3-one-17.beta.-carboxylic acid are both active inhibitors of testosterone-5.alpha.-reductase in vitro. Topical application of either testosterone or 5.alpha.-dihydrotesterone caused enlargement of the female hamster flank organ, an androgen dependent sebaceous structure. However, concomitant administration of 4-androsten-3-one-17.beta.-carboxylic acid, or its methyl ester, inhibited the response elicited by testosterone but did not inhibit the response elicited by 5.alpha.-dihydrotestosterone. These results indicated that the compounds are antiandrogenic by virtue of their ability to inhibit testosterone-5.alpha.-reductase. A number of 4-azasteroid compounds are known. See, for example, U.S. Pat. Nos. 2,227,876; 3,239,417; 3,264,301; and 3,285,918; French Pat. No. 1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640 (1973); Doorenbos and Brown, J. Pharm. Sci., 60 8, pp. 1234-1235 (1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974). In addition, U.S. Patents 4,377,584 and 4,220,775 of Rasmusson et al., described a group of 4-aza-17.beta.-substituted-5.alpha.-androstan-3-ones which are said to be useful in the treatment of hyperandrogenic conditions. Furthermore, in U.S. Patent 4,760,071, Rasmusson et al., disclosed novel 17.beta.N-(monosubstituted)carbamoyl-4-aza-5.alpha.-androst-1-ene-3-ones, which are highly potent testosterone-5.alpha.-reductase inhibitors. The processes known in the art for preparing the aformentioned compounds generally include a step wherein a double bond is introduced into the lactam ring of the azasteroid. Thus, selenic anhydride oxidation [Back, T.G., J. Org. Chem., 46, 1442 (1981)], sulfoxide elimination [U.S. Patent No. 4,377,584; 4,220,775], and silylation mediated DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) oxidation have all been used heretofore for the introduction of the .DELTA.-1 olefin functionality. The instant invention discloses a method whereby a powerful silylating reagent mediates regiospecific electrophilic substitution on the lactam ring to produce a versatile array of azasteroid derivatives substituted at the .alpha.-methylenic carbon. These derivatives are useful, through elimination of the added substituents, for making the .DELTA.1-olefin azasteroid derivative having potent 5-.alpha. reductase inhibitory activity. |
priorityDate | 1990-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.